1. Guest, the 'News in Brief' for the week beginning 8th August 2022 is here.
    Dismiss Notice
  2. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Open USA Alabama: 2019 - 2022 Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714,

Discussion in 'Recruitment into current ME/CFS research studies' started by Andy, Feb 5, 2022.

  1. Andy

    Andy Committee Member

    Messages:
    17,128
    Location:
    Hampshire, UK
    Brief Summary:
    The primary objective of this study is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET radiopharmaceutical [F-18]DPA-714 in individuals with chronic pain and fatigue suspected to be associated with neuroinflammation. The PET tracer [F-18]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation. The primary objective of this study is to determine if pain and fatigue patients have higher levels of neuroinflammation than HC individuals as measured with [F-18]DPA-714-PET/MRI.

    https://clinicaltrials.gov/ct2/show/NCT03759522
     
    Hutan, cfsandmore, nick2155 and 2 others like this.
  2. Hutan

    Hutan Moderator Staff Member

    Messages:
    20,169
    Location:
    Australia
    The latest update on this University of Alabama at Birmingham study was in Dec 2021. Looks like the end date is still some way off, so they probably are still recruiting.
    Recruiting:
    Healthy volunteer OR
    Clinical diagnosis of Multiple Sclerosis (MS) OR
    Meets 2016 American College of Rheumatology (ACR) case definition criteria for fibromyalgia OR
    Meets 1994 Fukuda case definition criteria for Chronic Fatigue Syndrome

    Shame about the use of Fukuda

    Jonathan McConathy is the researcher, there's an email address for him on the clinical trial registry link.
     

Share This Page